General Manager IST GmbH - Mannheim. 26th Annual EuroMeeting March 2014 ACV, Vienna Austria

Size: px
Start display at page:

Download "General Manager IST GmbH - Mannheim. 26th Annual EuroMeeting March 2014 ACV, Vienna Austria"

Transcription

1 EDC-System Selection From the point of view of small to mid-size CROs Steffen König General Manager IST GmbH - Mannheim 26th Annual EuroMeeting March 2014 ACV, Vienna Austria

2 Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug Information Association, Inc. ( DIA ), its directors, officers, employees, volunteers, members, chapters, councils, Special Interest Area Communities or affiliates, or any organization with which the presenter is employed or affiliated. These PowerPoint slides are the intellectual property of the individual presenter and are protected under the copyright laws of the United States of America and other countries. Used by permission. All rights reserved. Drug Information Association, DIA and DIA logo are registered trademarks or trademarks of Drug Information Association Inc. All other trademarks are the property of their respective owners.

3 Relevant CRO Facts Full-Service CRO 60 Employees 5 Statisticians 3 Statistical Programmer 11 Data Managers <10 ecrf Studies/year

4 Selection Process The vendor selection process aims at providing evidence that products and/or services delivered consistently meet particular requirements: Regulatory requirements Study- / Project requirements User requirements Budget requirements

5 Selection Process What do we expect from the EDC provider?

6 Environment Phase III Sponsor A NIS Phase I Sponsor B Lab-Data Questionnaires Med. Devices Phase II Sponsor C PASS Phase IV Sponsor D PASS Device Data Med. Devices Diagn. Tests

7 Administrative Requirements Beside standard administrative and standard functional requirements: Different environments must be reflected Clear cost structure Acceptance by sponsor Priority changes should be possible Changes in reasonable period of time Support of management processes

8 Selection Process What other considerations are important?

9 Vendor Characteristics Small EDC Provider Large EDC Provider Offices 1 5 Employees > Data center Languages 2 15 No. of projects per year > 500 Helpdesk 10 hrs at working days 7/24/365

10 Vendor Characteristics Small Vendor Has the vendor the capacity to setup the planned number of projects? Has the contact person a backup Does the vendor fulfill all technical reqirements? Is the vendor able to improve the services according to your requirements? Large Vendor Is the number of projects you ve planned of interest to the vendor? Do you have the same contact person and backup for all your projects Do you need all these opportunities? Is the vendor willing to improve the services according to your requirements?

11 At vendor site: Business Continuity Disaster recovery plan Back-ups in all key positions including management Mirror site Sound financial basis Escrow-Service

12 At CRO site: Business Continuity Emergency action plan Monitoring of Vendor (Risk Management) Personnel turnover, changes in management Major changes in company policy Changes in reliability or accuracy Yearly Feedback Meeting on Management level Use ESCROW service Have a second provider in reserve

13 Selection Process Experience from a vendor selection

14 Early Experience 1 st ecrf Selection Process (2006): Presentation of system at CRO by vendor Check if system meets our requirements Check of contract and costs Installation of ecrf test-system IT Test-Environment (Server etc.) Setup on local PCs for test-users

15 Early Experience Result (User): Very flexible All requirements fulfilled High performance Easy administration Clear cost structure This is the system we want Result (Auditor): Facilities not acceptable Back-ups not acceptable Documentation not acceptable SOP system not acceptable Business continuity not acceptable

16 Lessons Learned A clearly described selection process with involvement of all relevant parties is necessary to avoid: Mismatch with project needs Non-compliance with regulatory requirements Costs for needless installation and testing Redundant activities IT conflicts (capacity, system requirements)

17 Cross Functional Responsibilities All involved departments/functions must be involved in the selection process Task Study- / Project Requirements Technical Requirements (Hardware) Technical Requirements (Software) Budget Regulatory Requirements Vendor Qualification / Audit Responsible Project Manager IT Datamanagement / Project Manager Management / Finance QA QA

18 Relevant selection factors Vendor company size fits CRO size Number of projects Vendor capacity Technical requirements User requirements Communication (one face to the customer) Budget

19 Key to Success Cooperative partnership 1 Team: Sponsor & CRO & Vendor Open communication with visions how to improve processes Continuous improvement of technical services Mutual benefits

20 EDC-System Selection From the point of view of small to mid-size CROs Thank You!

Into the Clouds. Understanding How Cloud Computing Will Effect the Future of Regulated Content Management. Jennifer Goldsmith

Into the Clouds. Understanding How Cloud Computing Will Effect the Future of Regulated Content Management. Jennifer Goldsmith Into the Clouds Understanding How Cloud Computing Will Effect the Future of Regulated Content Management Jennifer Goldsmith Vice President, Veeva Vault Veeva Systems The views and opinions expressed in

More information

Pharmacovigilance Post July 2012 The new frontier

Pharmacovigilance Post July 2012 The new frontier Pharmacovigilance Post July 2012 The new frontier Colleen Walsh Head, Safety and Benefit Risk Management Quality, Biogen Idec 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria Disclaimer The

More information

Incorporating Risk- Based Monitoring Strategies: Challenges in Implementation Sherri Hubby, Director, U.S. Quality Assurance

Incorporating Risk- Based Monitoring Strategies: Challenges in Implementation Sherri Hubby, Director, U.S. Quality Assurance Incorporating Risk- Based Monitoring Strategies: Challenges in Implementation Sherri Hubby, Director, U.S. Quality Assurance 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria. Disclaimer The

More information

Project Management Standards Applied to Complex Clinical Trials. Disclaimer

Project Management Standards Applied to Complex Clinical Trials. Disclaimer Project Management Standards Applied to Complex Clinical Trials Alexander Gissler, PMP ProjectPharm Ltd., Owner & Director 1 Disclaimer The views and opinions expressed in the following PowerPoint slides

More information

Andrew Williams Senior Director European Medical Operations GlaxoSmithKline Company logo here. Disclaimer

Andrew Williams Senior Director European Medical Operations GlaxoSmithKline Company logo here. Disclaimer Fit for the future - A new strategic approach to Medical Information management within GSK Andrew Williams Senior Director European Medical Operations GlaxoSmithKline Company logo here 1 Disclaimer The

More information

High Quality or Poor Quality DB

High Quality or Poor Quality DB The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug Information Association, Inc. ( DIA ), its directors, officers,

More information

Sharing Regulatory Intelligence: Best Practices and Case Studies

Sharing Regulatory Intelligence: Best Practices and Case Studies Sharing Regulatory Intelligence: Best Practices and Case Studies Carolyn Hynes Sr. Director, Global Regulatory Intelligence, GlaxoSmithKline 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria

More information

Do Niche CROs have a Role in Drug Development?

Do Niche CROs have a Role in Drug Development? Do Niche CROs have a Role in Drug Development? Dr Nermeen Varawalla, MD, DPhil (Oxon), MBA President & CEO ECCRO 1 Disclaimer The views and opinions expressed in the following PowerPoint slides are those

More information

Constructing an etmf 12/2/2011. consider your current etmf structure!! The do s and don ts of EDM. Disclaimer

Constructing an etmf 12/2/2011. consider your current etmf structure!! The do s and don ts of EDM. Disclaimer Constructing an etmf The do s and don ts of EDM Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug

More information

esource What EDC Should Be Presenter: Ed Seguine President

esource What EDC Should Be Presenter: Ed Seguine President esource What EDC Should Be Presenter: Ed Seguine President The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug

More information

How to successfully Implement and Leverage the Regulatory Intelligence Function

How to successfully Implement and Leverage the Regulatory Intelligence Function How to successfully Implement and Leverage the Regulatory Intelligence Function Marianne Koehne EU RI Network Group; Global RI Manager Boehringer Ingelheim 26th Annual EuroMeeting 25-27 March 2014 ACV,

More information

Update on New MedDRA SOC Product issues

Update on New MedDRA SOC Product issues Update on New MedDRA SOC Product issues Judy Harrison, M.D. Chief Medical Officer, MedDRA MSSO ICSR Information Day 26 April 2016 London, UK Disclaimer The views and opinions expressed in the following

More information

QbD Approach and Regulatory Challenges in Japan

QbD Approach and Regulatory Challenges in Japan QbD Approach and Regulatory Challenges in Japan YOSHIHIRO MATSUDA Ph.D. Deputy Division Director Pharmaceuticals and Medical Devices Agency (PMDA) 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria

More information

The Safety Case as a basis for more effective outsourcing of writing of aggregate safety reports

The Safety Case as a basis for more effective outsourcing of writing of aggregate safety reports The Safety Case as a basis for more effective outsourcing of writing of aggregate safety reports Dr Brian Edwards Scientific Adviser, Pharmacovigilance & Drug Safety, NDA Regulatory Science Ltd DIA 3rd

More information

QPPV Association and Training Part 2 Session Introduction

QPPV Association and Training Part 2 Session Introduction QPPV Association and Training Part 2 Session Introduction Steve Douglas QPPV SGD Consulting Limited PrimeVigilance Ltd Disclaimer The views and opinions expressed in the following PowerPoint slides are

More information

Effective Project Leadership and Management: Disclaimer

Effective Project Leadership and Management: Disclaimer Effective Project Leadership and Management: A CRO Perspective Nita Ichhpurani, B.S., PMP Director, Drug Development Disclaimer The views and opinions expressed in the following PowerPoint slides are those

More information

Stakeholder education on biosimilar concepts - why does it matter globally?

Stakeholder education on biosimilar concepts - why does it matter globally? Stakeholder education on biosimilar concepts - why does it matter globally? Dr Virginia Acha Director, Regulatory Policy Europe, Middle East and Africa Amgen 26th Annual EuroMeeting 25-27 March 2014 ACV,

More information

SPL Use Case: Improving Compliance, Increasing Efficiencies, and Reducing Costs

SPL Use Case: Improving Compliance, Increasing Efficiencies, and Reducing Costs SPL Use Case: Improving Compliance, Increasing Efficiencies, and Reducing Costs Doris Sincak Project Supervisor Sanofi Disclaimers DIA The views and opinions expressed in the following PowerPoint slides

More information

Presenter: Ejaz Butt

Presenter: Ejaz Butt Presenter: Ejaz Butt Disclaimer The content and opinions expressed in the following PowerPoint slides are those of individuals who prepared the presentation and should not be attributed to Zigzag Associates

More information

Agency and Internal Labeling

Agency and Internal Labeling Agency and Internal Labeling Audits Joseph McMillian, MA Heartland Compliance Services LLC Internal Labeling Audits The views and opinions expressed in the following PowerPoint slides are those of the

More information

Promotional Materials. System Approach. Katie O Brien Associate Senior Consultant Global Quality Systems Eli Lilly and Company

Promotional Materials. System Approach. Katie O Brien Associate Senior Consultant Global Quality Systems Eli Lilly and Company Promotional Materials and a Quality Management System Approach Katie O Brien Associate Senior Consultant Global Quality Systems Eli Lilly and Company Disclaimer The views and opinions expressed in the

More information

How can Regulatory Agencies leverage the effectiveness of the Clinical Trials Enterprise

How can Regulatory Agencies leverage the effectiveness of the Clinical Trials Enterprise How can Regulatory Agencies leverage the effectiveness of the Clinical Trials Enterprise 10 th Latin American Conference on Clinical Research, October 2013 Xavier Luria, MD Drug Development and Regulation

More information

Using etechnologies to Increase Efficiency and Quality in Regulatory Operations

Using etechnologies to Increase Efficiency and Quality in Regulatory Operations Using etechnologies to Increase Efficiency and Quality in Regulatory Operations Tim Powell Submissions Management Global Regulatory Affairs Disclaimer The views and opinions expressed in the following

More information

Delivering GxP compliant mobile applications a practical case study. Presented by: Mark Stevens

Delivering GxP compliant mobile applications a practical case study. Presented by: Mark Stevens Delivering GxP compliant mobile applications a practical case study Presented by: Mark Stevens Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual

More information

Implementation of EU Falsified Medicines Directive

Implementation of EU Falsified Medicines Directive Implementation of EU Falsified Medicines Directive Gerald W Heddell Director, Inspection, Enforcement & Standards Division 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria Disclaimer The views

More information

Hands-on in Latin America Regulations for Clinical Trials

Hands-on in Latin America Regulations for Clinical Trials Hands-on in Latin America Regulations for Clinical Trials Director: Silvia Zieher VP Clinical Development, Latin America Operations INC Research Disclaimer The views and opinions expressed in the following

More information

How to Implement a Successful e-archiving Function Within a Multinational Company

How to Implement a Successful e-archiving Function Within a Multinational Company How to Implement a Successful e-archiving Function Within a Multinational Company Huguette BESSARD Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual

More information

New Regulation in Japan and Future Direction of PMDA. Tatsuya Kondo, M.D., Ph.D. Chief Executive Pharmaceuticals and Medical Devices Agency (PMDA)

New Regulation in Japan and Future Direction of PMDA. Tatsuya Kondo, M.D., Ph.D. Chief Executive Pharmaceuticals and Medical Devices Agency (PMDA) New Regulation in Japan and Future Direction of PMDA Tatsuya Kondo, M.D., Ph.D. Chief Executive Pharmaceuticals and Medical Devices Agency (PMDA) 1 Disclaimer The views and opinions expressed in the following

More information

Structured Content Management [SCM]

Structured Content Management [SCM] Structured Content Management [SCM] Lessons learned from SCM implementations Shailesh Shah ArborSys Group Ole Rom Andersen CEO, DITA Exchange Inc. The views and opinions expressed in the following PowerPoint

More information

Labelling Harmonization 2011

Labelling Harmonization 2011 Labelling Harmonization 2011 DIA, Bethesda, MD Core Labeling During Clinical Development Su Yueh Lin Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual

More information

Acronis ACRONIS ACCESS ADVANCED

Acronis ACRONIS ACCESS ADVANCED Acronis 2002-2014 ACRONIS ACCESS ADVANCED The proliferation of mobile devices into the enterprise is deeply impacting how people go about accomplishing their daily jobs. Mobile devices can t do everything

More information

Project Management Competencies. Disclaimer 28/06/2011

Project Management Competencies. Disclaimer 28/06/2011 Project Management Competencies Martin D. Hynes III, Ph.D. Senior Director Product Research & Development Lilly Research Laboratories Eli Lilly and Company Indianapolis, IN Disclaimer The views and opinions

More information

PMDA Update. - New Regulation in Japan and Future Direction of PMDA

PMDA Update. - New Regulation in Japan and Future Direction of PMDA PMDA Update - New Regulation in Japan and Future Direction of PMDA Kazuhiro SHIGETO, M.D., M.P.H., Ph.D. Executive Director, Pharmaceuticals and Medical Devices Agency (PMDA) 1 Disclaimer The views and

More information

Achieves International Standards

Achieves International Standards Rising to Excellence How a China CRO Achieves International Standards Helen Yin, VP & GM Tigermed-MacroStat Minzhi Liu, GM, MacroStat July 7 th, 2012 1 Outline Selecting excellent staff Training staff

More information

Utilities and Pitfalls of Modeling & Simulation in Pivotal Trials

Utilities and Pitfalls of Modeling & Simulation in Pivotal Trials Utilities and Pitfalls of Modeling & Simulation in Pivotal Trials H.M. James Hung, Ph.D Div. of Biometrics I, OB/OTS/CDER U.S. Food and Drug Administration Presented in PhRMA/FDA Workshop, October 28,

More information

PMDA Town Hall. Tatsuya KONDO, M.D., Ph.D. Chief Executive Pharmaceuticals and Medical Devices Agency (PMDA)

PMDA Town Hall. Tatsuya KONDO, M.D., Ph.D. Chief Executive Pharmaceuticals and Medical Devices Agency (PMDA) PMDA Town Hall - New Regulation in Japan and Future Direction of PMDA Tatsuya KONDO, M.D., Ph.D. Chief Executive Pharmaceuticals and Medical Devices Agency (PMDA) 1 Disclaimer The views and opinions expressed

More information

QbD approach and Regulatory Challenges in Europe

QbD approach and Regulatory Challenges in Europe QbD approach and Regulatory Challenges in Europe DIA 26th Annual EuroMeeting, Vienna 2014 Dr Peter Richardson Head of Quality, European Medicines Agency An agency of the European Union Disclaimer The views

More information

NAS and KAS Industry perspective

NAS and KAS Industry perspective NAS and KAS Industry perspective Henk Schuring Group Vice President Regulatory Affairs Europe Genzyme Europe BV, Netherlands 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria Disclaimer The

More information

Quality Management System Manual

Quality Management System Manual SpecSys, Inc. recognizes its responsibility as a provider of quality products and services. To this end, SpecSys, Inc. has documented, implemented and maintains a System that complies with ISO 9001 2000.

More information

Eugène van Puijenbroek, MD, PhD

Eugène van Puijenbroek, MD, PhD Signal detection and signal management at the Netherlands Pharmacovigilance il Centre EudraVigilance Information Day 1 July 2009 Eugène van Puijenbroek, MD, PhD Disclaimer The views and opinions expressed

More information

Effective application of Risk Management techniques to Drug Safety: a pragmatic approach

Effective application of Risk Management techniques to Drug Safety: a pragmatic approach Effective application of Risk Management techniques to Drug Safety: a pragmatic approach Dr Mark Perrott WCI Consulting ltd 19th October 2009 1 Disclaimer The views and opinions expressed in the following

More information

Data standardization and advancing regulatory science

Data standardization and advancing regulatory science Data standardization and advancing regulatory science Yoshiaki Uyama, Ph.D. Pharmaceuticals & Medical Devices Agency (PMDA) Visiting Professor, Graduate School of Medicine, Chiba University Visiting Professor,

More information

Computerised Systems. Inspection Expectations. Paul Moody, Inspector. 18/10/2013 Slide 1. ISPE GAMP COP Ireland Meeting, Dublin, 17 th October 2013

Computerised Systems. Inspection Expectations. Paul Moody, Inspector. 18/10/2013 Slide 1. ISPE GAMP COP Ireland Meeting, Dublin, 17 th October 2013 Computerised Systems Inspection Expectations ISPE GAMP COP Ireland Meeting, Dublin, 17 th October 2013 Paul Moody, Inspector Slide 1 Presentation Contents Brief Introduction to the IMB Regulatory References

More information

Current Regulatory Considerations and Challenges for Continuous Manufacturing of Pharmaceuticals

Current Regulatory Considerations and Challenges for Continuous Manufacturing of Pharmaceuticals 15th DIA Japan Annual Meeting 2018 Promoting Better Collaboration to Drive Global Health and Innovation in an Era of Medical and Scientific Transformation November 11-13, 2018 Tokyo Big Sight V5-S3 Current

More information

Computer System Validation & Backup

Computer System Validation & Backup REFERENCE: VERSION NUMBER: 1.1 EFFECTIVE DATE: 28-03-18 REVIEW DATE: 28-03-20 AUTHOR: Clinical Trials Manager, Clinical Trials Officer REVIEWED BY: R&I Senior Team APPROVED BY: Deputy Director of Research

More information

QUALITY ASSURANCE. Pharma Quality Agreements: What Are They, and Why They Matter For Your Study ABSTRACT

QUALITY ASSURANCE. Pharma Quality Agreements: What Are They, and Why They Matter For Your Study ABSTRACT WHITE PAPER PRESENTED BY PREMIER RESEARCH Pharma Quality Agreements: What Are They, and Why They Matter For Your Study ABSTRACT Quality Agreements are an effective bridge to a successful future for companies

More information

Quality and Compliance: The Core of the Life Science Learning System

Quality and Compliance: The Core of the Life Science Learning System Quality and Compliance: The Core of the Life Science Learning System By Rob Sims, Director, Life Science, UL EduNeering Executive Summary: Quality and Compliance The Core of the Life Science Learning System

More information

Transforming Regulatory Affairs through Technology - End to End Tech Platform Approach

Transforming Regulatory Affairs through Technology - End to End Tech Platform Approach Transforming Regulatory Affairs through Technology - End to End Tech Platform Approach Peter Lassoff, PharmD, FTOPRA VP & Head, Global Regulatory Affairs IQVIA Disclaimer The views and opinions expressed

More information

33rd SQA Annual Meeting, National Harbor, MA, USA Session C // Presentation C 2 28 March 2017 // 1:30 3:00 PM // V1.0

33rd SQA Annual Meeting, National Harbor, MA, USA Session C // Presentation C 2 28 March 2017 // 1:30 3:00 PM // V1.0 Computerized Systems Using Artificial Intelligence (AI) Components in a Regulated Environment: Implications on and Challenges of Establishing a Validated State René Kasan NNIT Switzerland AG Zürich, Switzerland

More information

Procedures in Regard to Entire Product Information Dr. Klaus Menges BfArM Bethesda (MD) October 14, 2011

Procedures in Regard to Entire Product Information Dr. Klaus Menges BfArM Bethesda (MD) October 14, 2011 Harmonization of Labeling Across Products with Same Active Moiety in the EU Procedures in Regard to Entire Product Information Texts Dr. Klaus Menges BfArM Bethesda (MD) October 14, 2011 Disclaimer The

More information

Scope of Compellent Health Check Services

Scope of Compellent Health Check Services Service Description Dell Compellent SAN Health Check Service Overview This Service Description ( Service Description ) is entered among you the customer ( you or Customer ) and the Dell entity identified

More information

Designing an Efficient IT Infrastructure. Lee Yee Ming 24 April 2014

Designing an Efficient IT Infrastructure. Lee Yee Ming 24 April 2014 Designing an Efficient IT Infrastructure Lee Yee Ming 24 April 2014 Designing an Efficient IT Infrastructure: Contents Identifying Needs 1. MDIC s Mandate and Operations 2. MDIC s IT Risk Management Designing

More information

Pharmacovigilance in Asia: The China Perspectives. Disclaimer

Pharmacovigilance in Asia: The China Perspectives. Disclaimer Pharmacovigilance in Asia: The China Perspectives Rebecca Wang, MD, FRCP, FACC Head, Product Development Drug Safety Operation, Asia Pacific Roche Shanghai Disclaimer The views and opinions expressed in

More information

The SaaS LMS and Total Cost of Ownership in FDA-Regulated Companies

The SaaS LMS and Total Cost of Ownership in FDA-Regulated Companies The SaaS LMS and Total Cost of Ownership in FDA-Regulated Companies The SaaS LMS and Total Cost of Ownership in FDA-Regulated Companies By Rob Sims, UL Compliance to Performance When Life Sciences companies

More information

What is an ideal PSUR? A new focus based on aligned expectations

What is an ideal PSUR? A new focus based on aligned expectations What is an ideal PSUR? A new focus based on aligned expectations Margarida Guimarães PRAC Member INFARMED, I.P. Periodic Safety Update Report Information Day 28 October 2016 London, UK Disclaimer The views

More information

FDA Requirements 5/16/2011. FDA and new IND regs. Changes on the horizon: CIOMS IX ICH upcoming initiatives

FDA Requirements 5/16/2011. FDA and new IND regs. Changes on the horizon: CIOMS IX ICH upcoming initiatives Session Overview (1) Although the role of the Qualified Person responsible for Pharmacovigilance is mandated by the European legislation, the QPPV is held responsible for the establishment and the maintenance

More information

Oracle Health Sciences Adverse Event Integration Pack for Oracle Health Sciences InForm and Oracle Argus Safety

Oracle Health Sciences Adverse Event Integration Pack for Oracle Health Sciences InForm and Oracle Argus Safety Oracle Health Sciences Adverse Event Integration Pack for Oracle Health Sciences InForm and Oracle Argus Safety Release Notes Release 1.0.2 E50819-01 December 2013 Overview The Oracle Health Sciences Adverse

More information

11 Hidden Features of electronic Trial Master Files (etmfs) to Optimize the Value of Your etmf

11 Hidden Features of electronic Trial Master Files (etmfs) to Optimize the Value of Your etmf 11 Hidden Features of electronic Trial Master Files (etmfs) to Optimize the Value of Your etmf Penelope K. Manasco, M.D. CEO MANA RBM pmanasco@manarbm.com etmfs are rapidly replacing paper trial master

More information

TABLE OF CONTENTS WATER SERVICES ASSOCIATION OF AUSTRALIA PROCESS BENCHMARKING AUDIT PROTOCOLS COPYRIGHT:... 3

TABLE OF CONTENTS WATER SERVICES ASSOCIATION OF AUSTRALIA PROCESS BENCHMARKING AUDIT PROTOCOLS COPYRIGHT:... 3 WATER SERVICES ASSOCIATION OF AUSTRALIA AUDIT PROTOCOL FOR THE AQUAMARK ASSET MANAGEMENT PROCESS BENCHMARKING PROJECT DECEMBER 2007 TABLE OF CONTENTS COPYRIGHT:... 3 1.0 INTRODUCTION:... 4 1.1 OVERVIEW...

More information

Labelling & Naming. European Biosimilars Group (EBG) perspective. >400 Million patient days worldwide clinical experience with EU biosimilar medicines

Labelling & Naming. European Biosimilars Group (EBG) perspective. >400 Million patient days worldwide clinical experience with EU biosimilar medicines Labelling & Naming European Biosimilars Group (EBG) perspective >400 Million patient days worldwide clinical experience with EU biosimilar medicines Elke Grooten, Director Public Affairs Sandoz Europe

More information

Revision of the Variations Regulation. Key Principles and Guidelines Development CONTENT

Revision of the Variations Regulation. Key Principles and Guidelines Development CONTENT DIA/EMEA/CMD(h) Conference London 26 October 2009 Revision of the Variations Regulation - Key Principles and Guidelines Development Hilde Boone EMEA 1 1 CONTENT 1. Background & revision status 2. Types

More information

Vendor-Sponsor Successful Communication. Nathalie Dutil Nov 2012

Vendor-Sponsor Successful Communication. Nathalie Dutil Nov 2012 Vendor-Sponsor Successful Communication Nathalie Dutil Nov 2012 It s all about setting expectations. Lack of communication Miscommunication Presentation overview Strategic Sourcing Oversight Model Trust

More information

SCHOOL DISTRICT BUSINESS LEADER

SCHOOL DISTRICT BUSINESS LEADER SCHOOL DISTRICT BUSINESS LEADER Test Design The School District Business Leader assessment consists of two tests. Each test contains a section with multiple-choice questions and a section with written

More information

Central Monitoring by Data Management Edit checks, logical checks, automatic review of data, trend analyses

Central Monitoring by Data Management Edit checks, logical checks, automatic review of data, trend analyses Central Monitoring by Data Management Edit checks, logical checks, automatic review of data, trend analyses Michel Arnoult mmb@arnoult.org Stockholm 22 September 2015 Agenda DM Contribution to Data Quality

More information

Creating a Computer Security Incident Response Team Action Plan

Creating a Computer Security Incident Response Team Action Plan Creating a Computer Security Incident Response Team CERT Training and Education Networked Systems Survivability Software Engineering Institute Carnegie Mellon University This material is approved for public

More information

The Patient-Reported Outcome (PRO) Consortium:

The Patient-Reported Outcome (PRO) Consortium: The Patient-Reported Outcome (PRO) Consortium: A Collaborative Approach to PRO Instrument Development and Qualification Stephen Joel Coons, PhD Executive Director The views and opinions expressed in the

More information

Scientific Working Group on Digital Evidence

Scientific Working Group on Digital Evidence SWGDE Framework of a Quality Management System for Digital and Multimedia Disclaimer: As a condition to the use of this document and the information contained therein, the SWGDE requests notification by

More information

BlackBerry User Guide

BlackBerry User Guide Version 1.0 Copyright 2013, 2017, Oracle and/or its affiliates. All rights reserved. This software and related documentation are provided under a license agreement containing restrictions on use and disclosure

More information

CSV Inspection Readiness through Effective Document Control. Eileen Cortes April 27, 2017

CSV Inspection Readiness through Effective Document Control. Eileen Cortes April 27, 2017 CSV Inspection Readiness through Effective Document Control Eileen Cortes April 27, 2017 Agenda Background CSV Readiness CSV and Change Management Process Inspection Readiness Do s and Don ts Inspection

More information

Oracle Communications Pricing Design Center

Oracle Communications Pricing Design Center Oracle Communications Pricing Design Center Licensing Information User Manual Release 11.2 E98018-01 July 2018 Copyright 2018, Oracle and/or its affiliates. All rights reserved. This software and related

More information

Board of Directors Performance Self-Evaluation Questionnaire

Board of Directors Performance Self-Evaluation Questionnaire Board of Directors Performance Self-Evaluation Questionnaire Please check the number that best represents your opinion on each question or statement. In each case 1 is the least favorable response and

More information

ectd: A Clinical Reviewer s Experience Sarah M. Connelly, MD Medical Officer Division of Antiviral Products FDA

ectd: A Clinical Reviewer s Experience Sarah M. Connelly, MD Medical Officer Division of Antiviral Products FDA ectd: A Clinical Reviewer s Experience Sarah M. Connelly, MD Medical Officer Division of Antiviral Products FDA Disclaimer The views and opinions expressed in the following PowerPoint slides are those

More information

ENHANCING CLINICAL DATA QUALITY WITH SPECIALIZED FUNCTIONAL SERVICE PROVIDER MODEL

ENHANCING CLINICAL DATA QUALITY WITH SPECIALIZED FUNCTIONAL SERVICE PROVIDER MODEL Shaping the Future of Drug Development ENHANCING CLINICAL DATA QUALITY WITH SPECIALIZED FUNCTIONAL SERVICE PROVIDER MODEL Jim Baker Senior Vice President Clinical Research Services Cytel JIM BAKER Senior

More information

Development of Orphan Drugs Regulatory Viewpoints from PMDA

Development of Orphan Drugs Regulatory Viewpoints from PMDA Development of Orphan Drugs Regulatory Viewpoints from PMDA Ken Sakushima Office of Cellular and Tissue-based Products, Office of New Drug III Pharmaceuticals and Medical Devices Agency (PMDA) Disclaimer

More information

PMDA Perspectives on Companion Diagnostics Development in Japan. Reiko Yanagihara, Ph.D. Deputy Review Director Office of In Vitro Diagnostics, PMDA

PMDA Perspectives on Companion Diagnostics Development in Japan. Reiko Yanagihara, Ph.D. Deputy Review Director Office of In Vitro Diagnostics, PMDA PMDA Perspectives on Companion Diagnostics Development in Japan Reiko Yanagihara, Ph.D. Deputy Review Director Office of In Vitro Diagnostics, PMDA 1 Disclaimer Content Slide The views and opinions expressed

More information

Copyright 2012, Oracle and/or its affiliates. All rights reserved.

Copyright 2012, Oracle and/or its affiliates. All rights reserved. 1 Improving Data Management with Systems Integration and Next Generation Data Flow Rich Davies Director, Global Sales Consulting - HSGBU Safe Harbor Statement The following is intended to outline our general

More information

Panama City, Panama April, 12-15, Marcelo Mario Matos Moreira. The Brazilian Health Surveillance Agency (ANVISA)

Panama City, Panama April, 12-15, Marcelo Mario Matos Moreira. The Brazilian Health Surveillance Agency (ANVISA) DIA Latin American Regulatory Conference Panama City, Panama April, 12-15, 2011 Biosimilars/Biotechnology Marcelo Mario Matos Moreira Coordinator Office of Biological Products The Brazilian Health Surveillance

More information

CMC Workshop CMC Challenges in Japan. April Bethesda, MD. Yoshihiro Matsuda, Ph.D., PMDA Session 10

CMC Workshop CMC Challenges in Japan. April Bethesda, MD. Yoshihiro Matsuda, Ph.D., PMDA Session 10 CMC Workshop 2015 April 13-15 Bethesda, MD CMC Challenges in Japan Yoshihiro Matsuda, Ph.D., PMDA Session 10 Disclaimer The views and opinions expressed in the following PowerPoint slides are those of

More information

YOUR SUCCESS IS OUR GOAL. Company Profile. Riyadh Jeddah Saudi Arabia IRSAA BUSINESS SOLUTIONS

YOUR SUCCESS IS OUR GOAL. Company Profile. Riyadh Jeddah Saudi Arabia IRSAA BUSINESS   SOLUTIONS YOUR SUCCESS IS OUR GOAL Company Profile Riyadh Jeddah Saudi Arabia IRSAA BUSINESS WWW.IRSAA.COM SOLUTIONS Company Summary . ABOUT IRSAA OUTSOURCING, BUSINESS SOLUTIONS & SERVICE PROVIDER IRSAA is the

More information

ICT SPENDING PREDICTOR 2019

ICT SPENDING PREDICTOR 2019 ICT SPENDING PREDICTOR 2019 TARGET Information pack Revolutionize your sales planning, target identification, and account planning Which prospects have the largest ICT budgets? How much more should our

More information

NTGA Compliance & Operational Manager Due Diligence Process

NTGA Compliance & Operational Manager Due Diligence Process NORTHERN TRUST 2010 PROGRAM SOLUTIONS CONFERENCE Investment Solutions in an Uncertain World: WHAT S NEXT? NTGA Compliance & Operational Manager Due Diligence Process Allison K. Fraser VP & Sr. Compliance

More information

Sentinel EMS. Integrating Sentinel EMS Server Into Your Existing Back-Office Systems

Sentinel EMS. Integrating Sentinel EMS Server Into Your Existing Back-Office Systems Sentinel EMS Integrating Sentinel EMS Server Into Your Existing Back-Office Systems Copyrights and Trademarks Gemalto 2017. All rights reserved. Gemalto, the Gemalto logo, are trademarks and service marks

More information

Health Care CRM RFP Guide

Health Care CRM RFP Guide Audience Rx Health Care CRM RFP Guide Key questions for identifying the right CRM provider 2017 Advisory Board All Rights Reserved 1 advisory.com Health Care CRM RFP Guide Key questions for identifying

More information

Standard Operating Procedures

Standard Operating Procedures Auditing of a Technology Vendor Checklist This checklist is intended to be a guide to planning your next audit. The items here should be evaluated for completeness. It is crucial for both Quality and the

More information

Oracle Hospitality RES 3700 Enterprise Management. Installation Guide

Oracle Hospitality RES 3700 Enterprise Management. Installation Guide Oracle Hospitality RES 3700 Enterprise Management Installation Guide Release 5.7 E95852-01 May 2018 Oracle Hospitality RES 3700 Enterprise Management Installation Guide, Release 5.7 E95852-01 Copyright

More information

Primavera Project Delivery Application User s Guide

Primavera Project Delivery Application User s Guide Primavera Project Delivery Application User s Guide Version 9.11.0.0 December 2012 Legal Notices Oracle Primavera Project Delivery Application Copyright 1998, 2012, Oracle and/or its affiliates. All rights

More information

GCP Refresher and GCP/GCDMP Trends. in the CTN. Denise King, MS, RD, CCRA & Lauren Yesko, BS. Presented by:

GCP Refresher and GCP/GCDMP Trends. in the CTN. Denise King, MS, RD, CCRA & Lauren Yesko, BS. Presented by: GCP Refresher and GCP/GCDMP Trends Presented by: in the CTN Denise King, MS, RD, CCRA & Lauren Yesko, BS CTN WEB SEMINAR SERIES: A FORUM TO EXCHANGE RESEARCH KNOWLEDGE Produced by: CTN Training This training

More information

On the Case: HCL Bekaert

On the Case: HCL Bekaert Transitioning service providers and fine-tuning the global services approach Publication Date: 14 Aug 2014 Product code: IT0019-003359 Thomas Reuner Summary Catalyst Satisfaction with traditional, often

More information

CERT Resilience Management Model, Version 1.2

CERT Resilience Management Model, Version 1.2 CERT Resilience Management Model, Asset Definition and Management (ADM) Richard A. Caralli Julia H. Allen David W. White Lisa R. Young Nader Mehravari Pamela D. Curtis February 2016 CERT Program Unlimited

More information

Core Abilities Assessment

Core Abilities Assessment Core Abilities Assessment Frequently Asked Questions 888-298-6227 TalentLens.com Copyright 2007 NCS Pearson, Inc. All rights reserved. Copyright 2007 by NCS Pearson, Inc. All rights reserved. No part of

More information

OECD Working Group on Good Laboratory Practice. Template for submission of comments on draft GLP Guidance Documents. Instructions for Use

OECD Working Group on Good Laboratory Practice. Template for submission of comments on draft GLP Guidance Documents. Instructions for Use OECD Working Group on Good Laboratory Practice Template for submission of comments on draft GLP Guidance Documents Instructions for Use 1. First, please complete the table below giving the full name of

More information

Oracle Systems Optimization Support

Oracle Systems Optimization Support Oracle Systems Optimization Support Oracle Systems Optimization Support offerings provide customers with welldefined packaged services. Let Oracle Advanced Customer Support help you make the most of your

More information

Oracle Fusion Applications Workforce Development Guide. 11g Release 5 (11.1.5) Part Number E

Oracle Fusion Applications Workforce Development Guide. 11g Release 5 (11.1.5) Part Number E Oracle Fusion Applications Workforce Development Guide 11g Release 5 (11.1.5) Part Number E22777-05 June 2012 Oracle Fusion Applications Workforce Development Guide Part Number E22777-05 Copyright 2011-2012,

More information

Agenda. Best Practices for Marketing Your Business Continuity Program Outside the Organization. Introduction

Agenda. Best Practices for Marketing Your Business Continuity Program Outside the Organization. Introduction Best Practices for Marketing Your Business Continuity Program Outside the Organization Joanna D Aquanni SAS Brian Zawada Avalution Consulting Agenda Introduction Who Might Be Interested in Your Program

More information

Oracle Systems Optimization Support

Oracle Systems Optimization Support Oracle Systems Optimization Support Oracle Systems Optimization Support offering provides customers with welldefined packaged services. Let Oracle Advanced Customer Services help you make the most of your

More information

PMO Services Checklist

PMO Services Checklist PMO Services Checklist by IMPACTbyLaura.com Services Checklist This resource is a list of possible services and categories that you can consider when determining how you will drive IMPACT with your PMO.

More information

Medical Information Role in the Pharmaceutical Industry

Medical Information Role in the Pharmaceutical Industry www.arisglobal.com A White Paper Presented By ArisGlobal Medical Information Role in the Pharmaceutical Industry by Ome Ogbru, PharmD, SME, Medical Communications & Sanjay Kumar D, Product Marketing Manager

More information

Cloud & Accounting Treatment

Cloud & Accounting Treatment Cloud & Accounting Treatment NASC 2018 Conference March 22, 2018 Yash Acharya, Director S&L Management Consulting Table of contents 1. 2. What is cloud? Current Guidance 3. Impact Current guidance 4. 5.

More information

FEATURE SCOPE DESCRIPTION PUBLIC Feature Scope Description SAP SE or an SAP affiliate company. All rights reserved.

FEATURE SCOPE DESCRIPTION PUBLIC Feature Scope Description SAP SE or an SAP affiliate company. All rights reserved. FEATURE SCOPE DESCRIPTION PUBLIC 2018-09-21 2018 SAP SE or an SAP affiliate company. All rights reserved. THE BEST RUN Content 1 About this Document....3 2....4 2 P U B L I C Content 1 About this Document

More information

Oracle. Adaptive Intelligent Apps for CX Getting Started with Adaptive Intelligent Sales 18.10

Oracle. Adaptive Intelligent Apps for CX Getting Started with Adaptive Intelligent Sales 18.10 Oracle Adaptive Intelligent Apps for CX Getting Started with Adaptive Intelligent Sales 18.10 Part Number: E95993-04 Copyright 2018, Oracle and/or its affiliates. All rights reserved Authors: Adaptive

More information